Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 08, 2022 at 02:50 am IST
Share
Amphastar Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 120.13 million compared to USD 112.2 million a year ago. Net income was USD 15.87 million compared to USD 29.55 million a year ago. Basic earnings per share from continuing operations was USD 0.32 compared to USD 0.62 a year ago. Diluted earnings per share from continuing operations was USD 0.3 compared to USD 0.59 a year ago.
For the nine months, sales was USD 363.96 million compared to USD 316.88 million a year ago. Net income was USD 57.47 million compared to USD 42.36 million a year ago. Basic earnings per share from continuing operations was USD 1.18 compared to USD 0.89 a year ago. Diluted earnings per share from continuing operations was USD 1.09 compared to USD 0.85 a year ago.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
AMPHASTAR PHARMACEUTICALS, INC. 
